SOAT1 and glioblastoma: Because strategies based on the vulnerability of one or two key molecules are not likely to be generalized to the entire patient population, continued efforts on screening and validating biomarkers to stratify patients suitable for JAK/STAT combination therapy are critical to improving our understanding of GBM.